Control del embarazo en pacientes con lupus eritematoso sistémico/síndrome antifosfolípido. parte 2: seguimiento del embarazo

Objective: In order to agree on the fundamental aspects related to the management of pregnancy in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), the Spanish Societies of Gynaecology and Obstetrics, Internal Medicine and Rheumatology set up a working group for t...

Descripción completa

Detalles Bibliográficos
Autores: Rodríguez Almaraz, Esther, Sáez Comet, Luis, Casellas, Manel, Delgado, Paloma, Ugarte, Amaia, Vela Casasempere, Paloma, Martínez Sánchez, Nuria, Galindo Izquierdo, Maria, Espinosa, Gerard, Marco, Beatriz, Martínez López, Juan Antonio, Robles, Angel, Martínez Taboada, Víctor Manuel, Bartha, Jose Luis, Ruiz Irastorza, Guillermo
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:español
inglés
OAI Identifier:oai:repositorio.unican.es:10902/21533
Acceso en línea:http://hdl.handle.net/10902/21533
Access Level:acceso abierto
Palabra clave:Anticoncepción
Antiphospholipid Syndrome
Contraception
Embarazo
Lactancia
Lactation
Lupus Eritematoso Sistémico
Pregnancy
Puerperio
Puerperium
Systemic Lupus Erythematosus
Síndrome Antifosfolípido
Descripción
Sumario:Objective: In order to agree on the fundamental aspects related to the management of pregnancy in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), the Spanish Societies of Gynaecology and Obstetrics, Internal Medicine and Rheumatology set up a working group for the preparation of three consensus documents. Methods: Each of the Scientific Societies involved proposed five representatives based on their experience in the field of pregnancy control in patients with autoimmune diseases. The recommendations were developed following the Delphi methodology. Results: This second document contains the recommendations regarding the management of pregnancy in women with SLE and APS, including complications such as lupus activity, congenital heart block, thrombotic and obstetric manifestations of APS and placental vascular disease. Conclusions: These multidisciplinary recommendations are considered decision-making tools for clinicians involved in the care of patients with SLE/APS during pregnancy.

Similares en LA Referencia